Dr Lorenzo Falchi speaks to ecancer about results from the EPCORE FL-1 trial presented at ASH 2025. This was a phase 3 study evaluating a bispecific antibody regimen in relapsed or refractory follicular lymphoma.

Dr Falchi reports that epcoritamab combined with rituximab and lenalidomide significantly improved overall response rate, complete response rate, and progression-free survival compared with rituximab and lenalidomide alone. The combination achieved an overall response rate of 95.7% and reduced the risk of progression or death by 79%.

He explains that benefits were consistent across high-risk subgroups, including patients with refractory disease and early progression.

Dr Falchi suggests that epcoritamab plus rituximab and lenalidomide could become a new outpatient, chemotherapy-free standard of care for patients with relapsed or refractory follicular lymphoma.